I make that three new significant contracts announced in the last couple of months (UPMC Health Plan), Tyson Foods and now Marsh McLennan with a total annual recurring revenue of approximately US$7.0m which is roughly 12% of annual revenue guidance of FY23 of US$55-58m. Cash flow positive must be insight.
